AI Article Synopsis
- Tumor evasion is linked to HHLA2, a new member of the B7 family, often found in PDL-1 tumors, which interacts differently with immune cells by either stimulating or inhibiting them.
- A study compared two monoclonal antibodies targeting CD28H, showing that specific targeting can enhance NK-cell activation and boost their ability to combat cancer cells.
- Analysis of clear cell renal cancer indicated the presence of CD28H NK cells in HHLA2 tumors, suggesting potential for effective treatment using tailored anti-CD28H antibodies.
Article Abstract
Tumor evasion has recently been associated with a novel member of the B7 family, HERV-H LTR-associating 2 (HHLA2), which is mostly overexpressed in PDL-1 tumors. HHLA2 can either induce a costimulation signal when bound to CD28H or inhibit it by binding to KIR3DL3 on T- and NK cells. Given the broad distribution of CD28H expression on NK cells and its role, we compared two monoclonal antibodies targeting this novel NK-cell engager in this study. We show that targeting CD28H at a specific epitope not only strongly activates Ca flux but also results in NK-cell activation. CD28H-activated NK cells further display increased cytotoxic activity against hematopoietic cell lines and bypass HHLA2 and HLA-E inhibitory signals. Additionally, scRNA-seq analysis of clear cell renal cancer cells revealed that HHLA2 clear cell renal cancer cell tumors were infiltrated with CD28H NK cells, which could be targeted by finely chosen anti-CD28H Abs.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/eji.202350901 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!